UBS lowered the firm’s price target on Edwards Lifesciences (EW) to $90 from $94 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Leans Into Growth After Strong Quarter
- Edwards Lifesciences price target lowered to $89 from $92 at Truist
- Edwards Lifesciences price target lowered to $87 from $90 at Baird
- Edwards Lifesciences: Capitalizing on TAVR Tailwinds, New Structural Heart Catalysts, and Attractive Valuation Upside
- Edwards Lifesciences: Sustained TAVR Momentum, Margin Upside, and New LAAC Growth Support Buy Rating